Cellectar Biosciences(CLRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLRB Cellectar Biosciences

Trading 07-21 12:43:16 EDT

2.59

+0.07

+2.78%

High2.63	Low2.53	Vol8.78K
Open2.53	D1 Closing2.52	Amplitude3.97%
Mkt Cap20.70M	Tradable Cap20.12M	Total Shares7.99M
T/O22.71K	T/O Rate0.11%	Tradable Shares7.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLRB","market":"US","secType":"STK","nameCN":"Cellectar Biosciences","latestPrice":2.59,"timestamp":1784651689791,"preClose":2.52,"halted":0,"volume":8779,"delay":0,"changeRate":0.027777777777777714,"floatShares":7767933,"shares":7991799,"eps":-7.4139,"marketStatus":"Trading","change":0.07,"latestTime":"07-21 12:43:16 EDT","open":2.53,"high":2.63,"low":2.53,"amount":22710.960467599998,"amplitude":0.039683,"askPrice":2.63,"askSize":200,"bidPrice":2.56,"bidSize":218,"shortable":3,"etf":0,"ttmEps":-7.4139,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1784664000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.52,"preHourTrading":{"tag":"盘前","latestPrice":2.51,"preClose":2.52,"latestTime":"09:27 EDT","volume":195,"amount":490.117719,"timestamp":1784640470189,"change":-0.01,"changeRate":-0.003968,"amplitude":0.150794},"postHourTrading":{"tag":"盘后","latestPrice":2.52,"preClose":2.52,"latestTime":"19:49 EDT","volume":201,"amount":506.43,"timestamp":1784591362067,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.093579,"impliedVol":1.1856,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/CLRB/tweets","defaultTab":"tweets","newsList":[{"id":"2653120917","title":"Cellectar Biosciences Publishes Corporate Presentation on Phospholipid Drug Conjugate Radiotherapy Pipeline, Led by Iopofosine I-131 in Waldenstrom Macroglobulinemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2653120917","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653120917?lang=en_us&edition=fundamental","pubTime":"2026-07-21 23:41","pubTimestamp":1784648515,"startTime":"0","endTime":"0","summary":"Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemiaCellectar BioSciences outlined plan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL6R2kRw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197","CLRB","BK1161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651450882","title":"Cellectar Reports Phase 1 Study Publication Supports Iopofosine I-131 Potential in Relapsed Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2651450882","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651450882?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:30","pubTimestamp":1784115059,"startTime":"0","endTime":"0","summary":"Cellectar reports Phase 1 study publication supports iopofosine I-131 potential in relapsed multiple myelomaCellectar BioSciences reported publication of Phase 1 results for iopofosine I 131 plus low-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDLbJ1Zjs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4588","CLRB","IE00BN0W2T93.GBP","BK4139","LU2095319765.USD","BCDF","NDAQ","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2V16.EUR","BK4112","LU0314104364.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014039.USD","IE00BN0W2W23.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651450829","title":"Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2651450829","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651450829?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:30","pubTimestamp":1784115000,"startTime":"0","endTime":"0","summary":"Demonstrated Favorable Safety Profile and Preliminary Clinical Activity inRelapsed/Refractory Multiple Myeloma Publication Supports Continued Development of Iopofosine I 131 as a Novel Targeted Radiot","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/15/3327602/29076/en/Cellectar-Biosciences-Announces-Publication-of-Phase-1-Study-of-Iopofosine-I-131-in-Peer-Reviewed-Journal-Cancers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211814178.USD","PDC","LU0175139822.USD","LU0124676726.USD","LU0158827781.USD","LU1892829315.USD","LU2023251221.USD","LU0289960550.SGD","LU0069063385.USD","LU2092937221.SGD","LU0094547139.USD","IDU","LU2089279066.USD","LU2125910336.SGD","LU2125910179.SGD","LU1923621640.USD","LU2413666699.HKD","LU2229751404.USD","BK4566","BK4534","BK4120","LU0289961442.SGD","LU1430594728.SGD","LU2028103732.USD","CNS","LU2463526074.USD","BK4533","BK4139","LU1721428933.USD","LU2362541273.HKD","LU1803068623.USD","LU2089284900.SGD","LU1712237335.SGD","LU1623119135.USD","LU2362541513.USD","LU0689626769.HKD","LU2106854487.HKD","LU2298064838.USD","EVX","LU0472753341.HKD","CLRB","LU0057025933.USD","LU2240825500.USD","LU0511384066.AUD","WM","LU0347712357.USD","BK4123","LU2362540622.SGD","BK4585","LU2238339852.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651695251","title":"Cellectar Biosciences initiated with a Buy at Brookline","url":"https://stock-news.laohu8.com/highlight/detail?id=2651695251","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651695251?lang=en_us&edition=fundamental","pubTime":"2026-07-13 05:55","pubTimestamp":1783893311,"startTime":"0","endTime":"0","summary":"Brookline initiated coverage of Cellectar Biosciences (CLRB) with a Buy rating and $15 price target Published first on TheFly – the ultimate source...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cellectar-biosciences-initiated-with-a-buy-at-brookline-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cellectar-biosciences-initiated-with-a-buy-at-brookline-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650130961","title":"Cellectar Biosciences Shareholders Approve Key Governance Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2650130961","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650130961?lang=en_us&edition=fundamental","pubTime":"2026-07-11 05:28","pubTimestamp":1783718922,"startTime":"0","endTime":"0","summary":"An announcement from Cellectar Biosciences ( ($CLRB) ) is now available. At its annual meeting held on July 7, 2026, Cellectar Biosciences’ shareho...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cellectar-biosciences-shareholders-approve-key-governance-measures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cellectar-biosciences-shareholders-approve-key-governance-measures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650913038","title":"Cellectar Biosciences Shareholders Approve 2 Million-share Increase to 2021 Stock Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2650913038","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650913038?lang=en_us&edition=fundamental","pubTime":"2026-07-11 05:14","pubTimestamp":1783718064,"startTime":"0","endTime":"0","summary":"Cellectar BioSciences shareholders approve 2 million-share increase to 2021 stock incentive planCellectar BioSciences held its annual shareholder meeting on July 7, 2026.Shareholders authorized an ame","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL89jKhM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642490612","title":"Cellectar BioSciences director Andrew Gu files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642490612","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642490612?lang=en_us&edition=fundamental","pubTime":"2026-06-10 05:01","pubTimestamp":1781038877,"startTime":"0","endTime":"0","summary":"Andrew Gu filed an initial Form 3 as a director of Cellectar Biosciences, citing a May 18, 2026 reporting date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL9H2LqZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640964676","title":"Cellectar BioSciences posts corporate presentation on iopofosine I-131 path toward accelerated approval in Waldenstrom macroglobulinemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2640964676","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640964676?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:12","pubTimestamp":1780344740,"startTime":"0","endTime":"0","summary":"Cellectar BioSciences posts corporate presentation on iopofosine I-131 path toward accelerated approval in Waldenstrom macroglobulinemia. Updated CLOVER-WaM efficacy showed ORR 83.6% and MRR 61.8% in the evaluable population; median duration of response 17.8 months.Median progression-free survival was 13.5 months; earlier-line patients showed longer median duration of response at 21.2 months.Regulatory strategy centered on a U.S. accelerated approval filing using CLOVER-WaM data; potential approval targeted for 2027.Phase 3 confirmatory study planned in post-BTK inhibitor patients, 200 total enrollment; estimated total study cost USD 42 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the ori","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL7P2lPX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","CLRB","02197","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640695184","title":"Cellectar says iopofosine I-131 posts 79.2% major response rate in Phase 2 CLOVER-WaM subgroup after BTK inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640695184","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640695184?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:10","pubTimestamp":1780315825,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences will present new Phase 2b CLOVER WaM subgroup results at ASCO on June 1, 2026.The analysis showed strong, durable responses for iopofosine I 131 in relapsed or refractory Waldenstrm macroglobulinemia following BTK inhibitor therapy.Tolerability was described as manageable, with severe side effects limited to blood-count reductions.The data supported a plan to seek US accelerated approval, with a Phase 3 confirmatory trial targeted for 4Q26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL2jpB4g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4139","CLRB","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951834","title":"Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951834","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951834?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:05","pubTimestamp":1780315500,"startTime":"0","endTime":"0","summary":"Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months inSubset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase 3 C","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304338/29076/en/Cellectar-Biosciences-to-Highlight-Compelling-New-Efficacy-Data-from-Phase-2b-CLOVER-WaM-Study-of-Iopofosine-I-131-in-r-r-Waldenstr%C3%B6m-Macroglobulinemia-at-the-American-Society-of-C.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2092937221.SGD","PDC","LU0347712357.USD","LU0158827781.USD","LU0124676726.USD","LU1430594728.SGD","BK4534","BK4588","LU2355687059.USD","LU1989772840.SGD","LU2413666699.HKD","LU0057025933.USD","BK4566","LU0472753341.HKD","LU0289960550.SGD","LU2089283258.USD","LU2413666426.HKD","LU0511384066.AUD","LU1917777945.USD","CLRB","BK4123","BK4120","LU2463526074.USD","LU2041044095.USD","LU2028103732.USD","CNS","WM","BK4107","LU2106854487.HKD","BK4117","LU1974910355.USD","LU2089279066.USD","LU2125910336.SGD","LU1585245621.USD","LU0289961442.SGD","LU0069063385.USD","LU2238339852.HKD","LU2240825500.USD","LU2023251221.USD","LU1623119135.USD","LU2111349929.HKD","LU2271345857.HKD","LU1989772923.USD","LU2362541513.USD","AFG","LU0158827948.USD","LU2229751404.USD","LU2125910179.SGD","LU2308191902.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636334818","title":"Cellectar Biosciences Bets on Iopofosine Breakthrough","url":"https://stock-news.laohu8.com/highlight/detail?id=2636334818","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636334818?lang=en_us&edition=fundamental","pubTime":"2026-05-20 13:19","pubTimestamp":1779254392,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences Inc (($CLRB)) has held its Q1 earnings call. Read on for the main highlights of the call. Cellectar Biosciences struck an opt...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cellectar-biosciences-bets-on-iopofosine-breakthrough?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cellectar-biosciences-bets-on-iopofosine-breakthrough?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636675558","title":"Cellectar Biosciences Files for Secondary Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2636675558","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636675558?lang=en_us&edition=fundamental","pubTime":"2026-05-20 05:24","pubTimestamp":1779225890,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences  filed a registration statement late Tuesday for the sale of up to 51.2 million common shares by the selling stockholders from time to time.The company will not receive any proceeds from the sale of shares by stockholders, but will receive proceeds from the cash exercise of any pre-funded warrants.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636396867","title":"Cellectar Biosciences files to sell 51.21M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2636396867","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636396867?lang=en_us&edition=fundamental","pubTime":"2026-05-20 05:10","pubTimestamp":1779225011,"startTime":"0","endTime":"0","summary":"17:08 EDT Cellectar Biosciences (CLRB) files to sell 51.21M shares of common stock for holders Published first on TheFly – the ultimate source for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cellectar-biosciences-files-to-sell-51-21m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cellectar-biosciences-files-to-sell-51-21m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636862795","title":"Cellectar Biosciences Inc - Files for Offering of up to 51.2 Mln Shares of Common Stock by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2636862795","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636862795?lang=en_us&edition=fundamental","pubTime":"2026-05-20 05:08","pubTimestamp":1779224894,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nFWN41W0N0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636004967","title":"Cellectar Biosciences Announces Board Changes and New Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2636004967","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636004967?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:01","pubTimestamp":1779141717,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Cellectar Biosciences ( ($CLRB) ). On May 17, 2026, Cellectar Biosciences director Stefan D. Loren notified the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cellectar-biosciences-announces-board-changes-and-new-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cellectar-biosciences-announces-board-changes-and-new-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636700151","title":"Cellectar BioSciences announces annual shareholder meeting notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2636700151","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636700151?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:02","pubTimestamp":1779138122,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences will hold its annual shareholder meeting virtually on July 7, 2026.Shareholders are set to vote on electing two Class III directors, including Andrew Gu and Douglas J. Swirsky.The meeting agenda also includes expanding the 2021 Stock Incentive Plan by 1,000,000 shares, approving a non-binding executive pay proposal, and authorizing the exercise of warrants covering up to 39,618,078 shares.Other items include ratifying Deloitte & Touche as auditor for the year ending Dec. 31, 2026, and a proposal to adjourn the meeting if needed to seek additional votes on the warrant exercise item.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news br","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL6Q2xgj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009874","title":"Cellectar Biosciences appoints Nantahala analyst Andrew Gu to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009874","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009874?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:17","pubTimestamp":1779135455,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences director Stefan D. Loren notified the board on May 17, 2026 that he will not stand for reelection as a Class III director at the 2026 annual meeting when his term expires.The decision was not tied to any disagreement over the company’s operations, policies, or practices.On May 18, 2026, the board appointed Andrew Gu as a Class III director.Gu is an analyst at Nantahala Capital Management, where he focuses on biotechnology investments.Gu was also named to the board’s audit committee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Sec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL39TWX9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635603248","title":"Cellectar Biosciences Coverage Assumed by Ladenburg Thalmann at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635603248","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635603248?lang=en_us&edition=fundamental","pubTime":"2026-05-16 03:41","pubTimestamp":1778874060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 15:41 ET (19:41 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635087016","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2635087016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635087016?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:20","pubTimestamp":1778851244,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Talphera (TLPH), Cellectar Biosciences (CLRB) and Ma...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-174?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-174?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","TLPH","XBI","BLSX","LU0029874061.USD","LU0128526141.USD","BK4137","CLRB","BK4581","BK4585","BK4112","BLSG","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635746062","title":"Cellectar Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635746062","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635746062?lang=en_us&edition=fundamental","pubTime":"2026-05-14 23:09","pubTimestamp":1778771367,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences Inc reports results for the quarter ended March 31 - Earnings SummaryCellectar Biosciences Inc CLRB.OQ reported a quarterly adjusted loss of $1.30 per share for the quarter ended","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R1TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cellectar.com","stockEarnings":[{"period":"1week","weight":-0.0418},{"period":"1month","weight":-0.0968},{"period":"3month","weight":-0.1127},{"period":"6month","weight":-0.3096},{"period":"1year","weight":-0.495},{"period":"ytd","weight":-0.1458}],"compareEarnings":[{"period":"1week","weight":-0.0095},{"period":"1month","weight":-0.0062},{"period":"3month","weight":0.054},{"period":"6month","weight":0.0827},{"period":"1year","weight":0.1825},{"period":"ytd","weight":0.0882}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.017624},{"month":2,"riseRate":0.666667,"avgChangeRate":0.024048},{"month":3,"riseRate":0.5,"avgChangeRate":-0.034403},{"month":4,"riseRate":0.25,"avgChangeRate":-0.094306},{"month":5,"riseRate":0.416667,"avgChangeRate":0.057843},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.0753},{"month":7,"riseRate":0.25,"avgChangeRate":-0.096067},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.013426},{"month":9,"riseRate":0.416667,"avgChangeRate":-0.024755},{"month":10,"riseRate":0.083333,"avgChangeRate":-0.159758},{"month":11,"riseRate":0.416667,"avgChangeRate":-0.062866},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.062943}],"exchange":"NASDAQ","name":"Cellectar Biosciences","nameEN":"Cellectar Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cellectar Biosciences(CLRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cellectar Biosciences(CLRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cellectar Biosciences,CLRB,Cellectar Biosciences股票,Cellectar Biosciences股票老虎,Cellectar Biosciences股票老虎国际,Cellectar Biosciences行情,Cellectar Biosciences股票行情,Cellectar Biosciences股价,Cellectar Biosciences股市,Cellectar Biosciences股票价格,Cellectar Biosciences股票交易,Cellectar Biosciences股票购买,Cellectar Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cellectar Biosciences(CLRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cellectar Biosciences(CLRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction